By John Michaels
AXIM Biotechnologies invented a cannabis gum with 5mg of CBD and 5mg of THC.
The medicinal purpose of their new cannabis gum is to relieve certain symptoms related to multiple sclerosis. The plan of this gum is to offer patients a non-smoking delivery option with little to no side effects.
The usual side effects of 11-Hyrdoxy-THC.
Medibles pass through the liver and break down into the chemical called 11-Hydroxy-THC. As the chemical passes through the body it further degrades into 8- and 9-Hydroxy-THC. 11-Hydroxy-THC is a metabolite known to cause unpredictable side effects that cause negative symptoms. The cannabis gum is supposed to limit the number of metabolites because the cannabinoids in the gum are absorbed through the cheeks and move straight into the bloodstream, avoiding the liver.
AXIM researchers prefer non-synthetic cannabinoids in their research.
Many people cringe at the idea of synthetic cannabinoids. The AXIM researchers are aware of that stigma but prefer to test with synthetic cannabinoids for two main reasons. One, the American FDA regulations have strict guidelines when it comes to researching a schedule I drug. The second, synthetic cannabinoids normally have a purity level over 99 percent.
AXIM has found it easier to get approval from the FDA using synthetic cannabinoids instead of natural varints. Natural cannabis includes a variety of cannabinoids (over 140) and over 400 terpenes that must be documented and reported to the FDA. Synthetic cannabinoids have far fewer impurity levels and are easier to report.
Phase 3 trials for cannabis gum to start in early 2018.
The AXIM researchers in the United Kingdom, Netherlands and the U.S. is hoping to start phase 3 testing by 2018. Dr. Anastassov is the lead researcher for cannabis gum and is hoping to bring legitimacy to the medicinal benefits of the cannabis plant. “I think the governments organizations, as rigid as they are, once the evidence is there, they will change their opinion. At least that’s my hope.”